Freedom Broker Rates Sanara MedTech (SMTI) buy, $35 Price Target

Freedom Broker has reiterated its buy rating for SMTI, with a price target of $35, a 53.91% upside from the current price.

By EarningsIQ Research Desk · Published Jun 17, 2026, 3:00 PM EDT · Updated Jun 18, 2026, 2:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Freedom Broker rated Sanara MedTech Inc. ($SMTI) "buy" with a $35 price target on June 17, 2026.

Since the rating, $SMTI is up 7.9% after 1 week, up 17.8% after 1 month and up 56.3% to date (from the $21.22 close on Jun 17, 2026).

SMTI Sanara MedTech Inc.

$33.16 +43.55% year to date

Daily close · Oct 16, 2026

Key Points

Freedom Broker reiterated their buy rating on SMTI with a target price of $35 on June 17, 2026.
Freedom Broker's $35 price target implies 53.91% upside from Sanara MedTech Inc.'s ($SMTI) current $22.74 share price.
SMTI shares are currently trading at $22.74, with several institutional investors adjusting their positions.
Insiders, including Ronald Nixon and Keith Myers, recently bought shares, while analysts maintain optimistic targets.

Get $SMTI trade alerts by text

We text you when insiders, Congress or big funds trade $SMTI. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Sanara MedTech Inc. alert may contain errors. Disclosures

Freedom Broker has reiterated its buy rating on SMTI, maintaining a price target of $35 as of June 17, 2026. This comes as SMTI shares trade at $22.74, suggesting potential upside according to the brokerage's analysis.

Other Institutional Activity in SMTI

Several institutional investors have been active in SMTI recently. BlackRock, Inc. increased its holdings by 14,893 shares, resulting in a total of 228,767 shares valued at approximately $3.93 million. Vanguard Capital Management LLC established a new position with 151,367 shares worth about $2.6 million. Stonebridge Wealth Management, LLC added 1,965 shares, bringing its total to 136,899 shares valued at $2.35 million. Royal Bank of Canada also grew its stake by 13,746 shares to reach 131,389 shares, valued at $2.26 million.

Sanara MedTech Inc. Stock Down 35.2%

SMTI shares are trading at around $22.74. The company has been drawing attention from both institutional investors and analysts, with a series of recent analyst ratings supporting a positive outlook.

12-month forecast

$SMTI price target

Sanara MedTech Inc. daily closes and this analyst's $35 target. Not advice.

Insider Buying and Selling at Sanara MedTech Inc.

On June 4, 2026, several insiders purchased shares of SMTI. Ronald Nixon, Keith Myers, Robert Andrew DeSutter, Eric Tanzberger, Sara Ortwein, and Eric Major each bought between 4,154 and 5,539 shares. These transactions were not under a pre-planned 10b5-1 trading plan.

Analysts Set New Price Targets

On June 17, 2026, Freedom Broker reiterated its buy rating on SMTI with a price target of $35. Previously, on April 15, 2026, Lake Street initiated coverage with a buy rating and a $32 target. HC Wainwright & Co. has consistently maintained a buy rating, with the latest reiterated target of $36 on January 26, 2026.

Bottom Line

Freedom Broker's reiterated buy rating and $35 price target for SMTI reflect continued confidence in the company's potential. Institutional and insider activity suggests a keen interest in the stock, while analyst ratings provide a positive outlook. As always, these reports are backward-looking and may not represent the current state of the company's prospects.